Dr. Peter Pack

Chairman

2023 - Current

NED of Antiverse

2022

Trustee

2020

The Gisela Pack Foundation supports German students with migration background studying medicine or science with studentships, study material and IT infrastructure

Senior Biotech Advisor to PE, VC, Biotechs

2019

NED, Mentor and Freelancer

Owner

2012

Due Diligences M&A Strategic Consulting Business Plan (Analysis, Formulation) Referee Function German Ministry of Research Board Member function Mentoring Interim Management

Member of the Board of Directors

2016 - 2020

Polyplus-transfection® SA is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics. Located close to the University of Strasbourg in France, Polyplus-transfection® is ISO 9001-certified since 2002 and supplies its wide range of transfection reagents through a worldwide distributor network. PolyPlus was partially acquired by Pincus Warburg in May of 2020.

CEO

2015 - 2019

Crescendo Biologics is developing potent and highly differentiated Humabody® VH therapeutics with a focus on cancer, specifically in the fields of Immune-Oncology (IO) and next generation Antibody Drug Conjugates (ADCs). Humabodies are substantially different from conventional antibodies or even antibody fragments in terms of size, format, multi-specificity and pharmacology. They are based on our proprietary, robust and highly efficient transgenic VH technology platform providing 100% human VH domains of minimal size (12 kDa). These VH domains are used as robust building blocks for the generation of mono- and multi-specific Humabodies. Our rapid plug & play technology enables us to unlock differentiated approaches with an immunoglobulin-derived structure of minimal size such as: combinatorial specificity bi-paratopic targeting tuneable internalization extended half-life. To leverage the advantages of our Humabody VH technology, we are building a pipeline of new therapeutics against a wide variety of targets in the IO field and as next generation ADCs. Humabodies and Humabody® Drug Conjugates (HDCs) show superior tissue penetration and tumour/background ratios in vivo with the potential of greatly improved therapeutic windows. Crescendo's lead programme is CB307, a novel trispecific approach to activate T-Cells only in the presence of tumour cells by a novel clustering mechanism. CB307 is currently in CMC and will enter the clinic in 2020.

Member of the Board of Directors

2014 - 2019

The Cambridge (UK)-based company builts a pipeline of valuable new therapeutics through in-house development and strategic partnerships that leverage the advantages of Humabody™ VH technology. Its pipeline includes Humabody programmes targeting dermatology and oncology indications such as checkpoint modulators. Inititially, Peter Pack represented EMBL Ventures in Crescendo's BoD as observer before he became member of the Board as CEO.

Managing Director, Partner

2013 - 2015

EMBL Ventures is an independent venture capital investor that manages two Funds on behalf of major European institutional and private investors, exclusively focusing on life-science investments. Six of our sixteen portfolio companies have generated to date a transaction volume of more than € 1.5 billion in risk sharing deals with Pharma partners.

Member of the Board of Directors

2013 - 2015

Independent BoD member up until trade sale to Roche. Signature Diagnostics (established by Prof. André Rosenthal and located in Potsdam near Berlin) is a pioneer in ultra-deep sequencing for the development of novel prognostic gene signatures for predicting outcome and drug response in colorectal and lung cancer patients. Signature Dx was acquired by Roche Dx in Februar, 2015.

Managing Director

2011 - 2012

Managing Director of European market leader for reference materials and proficiency testing with nearly 400 employees in 22 international locations; Exclusive European distributor for ATCC products.

Managing Director

2008 - 2011

Managing Director of largest independent German ophthalmology implant provider, responsibilities comprising development, marketing and sales of medical implants such as intra-ocular lenses for cataract patients in Germany, Poland and Hungary. The family owned company was acquired by Private Equity in February of 2011.